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Abstract
Background: High mitotic activity is associated with the genesis and progression of many cancers. Small molecule
inhibitors of mitotic apparatus proteins are now being developed and evaluated clinically as anticancer agents.
With clinical trials of several of these experimental compounds underway, it is important to understand the
molecular mechanisms that determine high mitotic activity, identify tumor subtypes that carry molecular aberrations
that confer high mitotic activity, and to develop molecular markers that distinguish which tumors will be most
responsive to mitotic apparatus inhibitors.
Methods: We identified a coordinately regulated mitotic apparatus network by analyzing gene expression profiles for
53 malignant and non-malignant human breast cancer cell lines and two separate primary breast tumor datasets. We
defined the mitotic network activity index (MNAI) as the sum of the transcriptional levels of the 54 coordinately
regulated mitotic apparatus genes. The effect of those genes on cell growth was evaluated by small interfering RNA
(siRNA).
Results: High MNAI was enriched in basal-like breast tumors and was associated with reduced survival duration and
preferential sensitivity to inhibitors of the mitotic apparatus proteins, polo-like kinase, centromere associated protein E
and aurora kinase designated GSK462364, GSK923295 and GSK1070916, respectively. Co-amplification of regions of
chromosomes 8q24, 10p15-p12, 12p13, and 17q24-q25 was associated with the transcriptional upregulation of this
network of 54 mitotic apparatus genes, and we identify transcription factors that localize to these regions and
putatively regulate mitotic activity. Knockdown of the mitotic network by siRNA identified 22 genes that might be
considered as additional therapeutic targets for this clinically relevant patient subgroup.
Conclusions: We define a molecular signature which may guide therapeutic approaches for tumors with high mitotic
network activity.
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Background
Studies of the molecular biology of cell division have
revealed an intricate network of structural proteins,
molecular motors, regulatory kinases and phospha-
tases that are required for error-free chromosome
segregation. Upregulation of the genes that encode
these proteins, the ensemble of which is referred to
hereafter as the mitotic apparatus network, is associ-
ated with genome instability [1], carcinogenesis [2–4],
and reduced survival duration [5]. As high mitotic ac-
tivity is associated with the genesis and progression
of many cancers, small molecule inhibitors of mitotic
apparatus proteins are now being developed and eval-
uated clinically as anticancer agents [5–10]. Proteins
currently being targeted include the polo-like kinase 1
(PLK1 [5]), the aurora kinases (AURKA) [11] and
(AURKB/C) [2, 12], centromere associated protein E
(CENPE) [13], and the kinesin spindle protein [14].
With clinical trials of several of these experimental
compounds commencing, it is important to under-
stand the molecular mechanisms that determine high
mitotic activity, identify tumor subtypes that harbor
molecular aberrations that confer high mitotic activity,
and to develop molecular markers that define tumors that
will be most responsive to mitotic apparatus inhibitors. It
is also important to understand how mitotic apparatus
protein inhibitors interact in order to guide combined
therapeutic strategies.
In a study of transcriptional networks in skin sam-
ples from M. musculus x M. spretus backcross mice,
Quigley et al. demonstrated that transcription of a
network of mitotic apparatus genes is influenced by
germline polymorphisms [15]. As germline polymor-
phisms associated with aspects of cancer genesis and/
or progression are sometimes enhanced in tumors by
selection of genomic aberrations that further alter
transcription of the target genes [15–17], we investi-
gated the possibility that the high mitotic network ac-
tivity characteristic of aggressive breast cancer is
influenced by genomic aberrations that accumulate
during breast cancer genesis and progression. Here
we show that co-amplification of transcription factors
that putatively target mitotic apparatus network genes
is strongly associated with increased transcriptional
activity of the mitotic apparatus network. We also
show that breast cancer cell lines with high mitotic
activity are preferentially sensitive to small molecule
inhibitors that target mitotic apparatus proteins PLK1,
CENPE and AURKB/C, designated GSK462364 [18, 19],
GSK923295 [13, 20], and GSK1070916 [21, 22], re-
spectively. Finally, we identify additional candidate
mitotic apparatus network targets and suggest strat-
egies to combine inhibitors to counter the develop-
ment of resistance.
Methods
Cell culture
The cell lines described in this study derived from 49
malignant and 4 non-malignant breast tissues and
growth conditions for the cell lines have been reported
previously [23].
Experimental compounds
The small-molecule inhibitors GSK1070916, GSK462364,
and GSK923295 were provided by GlaxoSmithKline Inc.
GSK462364 is a PLK inhibitor and is selective for PLK1
over PLK2 and PLK3 with Ki
app of 0.5 nM, 850 nM, and
1000 nM, respectively. GSK462364 has at least 1000-fold
selectivity for PLK1 compared to 48 other protein kinases
[19]. GSK1070916 is an ATP competitive inhibitor that is
selective for Aurora B and C with Kis of 0.38 and 1.5 nM,
respectively, and 250-fold selectivity over Aurora A [22].
GSK923295 is an allosteric inhibitor of CENPE with a Ki
of 3.2 nM. GSK923295 does not compete with either ATP
or microtubules and is highly selective for CENPE com-
pared to seven other kinesins [13]. Stock solutions were
made at a concentration of 10 mM in dimethyl sulfoxide
(DMSO) and stored at −20 °C. Compounds were diluted
(1:5 serial dilution) to produce test inhibitor concentra-
tions ranging from 0.0758 nM to 30 μM.
Cell viability/growth assay and dose response
(50 % growth inhibition (GI50))
Dose-response curves were determined according to the
National Cancer Institute NIH guidelines. In brief, cell
suspensions were aliquoted into 96-well plates in 100 μl
growth media. Inoculates were incubated for 24 hours at
37 °C for stabilization and then treated with nine doses
in triplicate for 72 hours. Cell proliferation was mea-
sured with CellTiter-Glo® Luminescent Cell Viability
Assay (Promega, Madison, WI, USA). Luminescence was
plotted after subtraction of the baseline (an estimate of
the number of the cells at time 0). Total growth inhib-
ition doses and 50 % growth inhibition (GI50) doses were
calculated by GraphPad Prism4 software (GraphPad
Software, Inc., La Jolla, CA, USA).
Datasets
The mitotic gene transcriptional network was assessed
in several published microarray data sets profiled with
Affymetrix GeneChip arrays (HG-U133A or HG-U133
Plus 2.0). These data include breast cancer [GEO:
GSE2034, GEO:GSE1456, and GEO:GSE4922], lung
cancer [GEO:GSE3141], ovarian cancer [GEO:GSE9891],
Wilms’tumor [GEO:GSE10320], prostate cancer [GEO:
GSE8128], glioma [GEO:GSE13041], acute lymphoblastic
leukemia [GEO:GSE12995], acute myelogenous leukemia
[GEO:GSE12417], and lymphoblast cell lines [GEO:
GSE11582]. Mitotic network activity was also examined
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in various normal tissues [GEO:GSE7307], including
normal breast tissue [GEO:GSE10780]. The relationship
between MNAI and survival among patients with breast
cancer was examined in four datasets (dataset 1:
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) with
accession number E-TABM-158; dataset 2: GSE2034;
dataset 3: GSE1456 and dataset 4: GSE4922). Data were
pre-processed as described in the original publications.
An additional breast cancer dataset (defined as Curtis
dataset) consisting of 1980 fresh-frozen primary breast
tumors, recently described by Curtis et al. was employed
for validation of the mitotic network gene signature and
associations between copy number and expression. For
all cases, the genome-wide copy number was assessed
on the Affymetrix single nucleotide polymorphism
(SNP) 6.0 platform and matched RNA was hybridized to
Illumina HT-12 bead arrays for gene expression analysis
(https://www.ebi.ac.uk/ega/studies/EGAS00000000083).
The dimensionality of the copy number data was re-
duced by merging regions with similar profiles across all
samples based on the CGH regions algorithm [24],
resulting in 2995 regions. The mitotic network activity
index (MNAI) was computed by utilizing probes with a
perfect transcriptomic match based on reannotation of
the Illumina platform [25]. Averages were taken when
multiple “perfect” or “good” probes were present on the
array. Probes annotated as “bad” were excluded from the
analysis, except when they were the only probe available
for a particular mitotic network gene (DEPDC1, GTSE1).
Samples were classified into the intrinsic subtypes based
on PAM50 [26] and the integrative clusters (IC) as de-
fined by Curtis et al [27].
Statistical analysis
The correlation among the cellular GI50 values of
GSK462364, GSK1070916 and GSK92325 was assessed
with the Pearson correlation test. Tumor expression pro-
files were clustered using the mitotic network genes.
Kaplan-Meier survival curves were generated for pa-
tients stratified into groups of high (upper tertile) and
low (lower tertile) MNAI to evaluate differences in
disease-free survival (DFS). For the cohort studied by
Curtis et al. we similarly generated Kaplan-Meier sur-
vival curves to evaluate differences in disease-specific
survival (DSS) and also fit a Cox proportional hazard
model that included MNAI, age, size (spline function),
lymph node positive (spline function), grade, stage, and
PAM50 as variables. Statistical analyses were performed
using the Statistical Package for the Social Sciences ver-
sion 11.5 (SPSS, Inc., Chicago, IL, USA) and the R pro-
ject for statistical computing (http://www.r-project.org/)
with the packages “survival” and “rms”. Association ana-
lyses were performed based on one at a time analysis of
variance (ANOVA) with copy number aberration (CNA)
as the predictor variable for each mitotic net expression
profile for both datasets from Chin et al. and Curtis
et al. Differences in the MNAI index across various breast
cancer subgroups was evaluated by ANOVA.
Network construction and functional annotation
A network of genes found to be significantly correlated
(Pearson correlation) with the mRNA expression levels of
PLK1, CENPE, or AURKB was constructed based on the
ExpressionCorrelation software tool (http://baderlab.org/
Software/ExpressionCorrelation). Correlations exceeding a
threshold were displayed as “edges” between two
“nodes” (where nodes represent genes), and this ap-
proach was used to define the 54-gene mitotic appar-
atus network and assess it in datasets 1–4. Network
figures were generated using Cytoscape version 2.5.1
(www.cytoscape.org). The gene ontology tool BiNGO
[28] was employed to test for statistical enrichment of
specific functional groups.
Transcription factor binding site analysis
Ensembl and HGNC gene identifiers were obtained for
the 54 mitotic network genes and their proximal promoter
sequences were extracted using the ENSEMBL Biomart
(GRCh37.p13). (http://grch37.ensembl.org/biomart/). Se-
quence regions 3000 immediately 5′ upstream from the
transcription start site and 1000 Kb downstream (includ-
ing the 5′ untranslated region (UTR)) were extracted.
Transcription factor binding site (TFBS) matrices were
obtained from the Transfac professional database (version
13.4) [29] and detected using the Match algorithm [30].
TFBS were detected with core and matrix similarity
thresholds of 1 and 0.85 respectively, together with pre-
calculated profiles that minimize both false positives and
negatives.
In order to determine whether the transcription factors
under investigation (MYC, ZEB1, FOXM1 and SOX9)
bind to their predicted binding sites within mitotic net-
work genes, we downloaded chromatin immunoprecipita-
tion (ChIP)-seq datasets from the ENCODE project and
other published studies spanning multiple human cell
types from the NCBI Short Read Archive (SRA). As data
from only one breast cancer cell line (MCF7) and non-
transformed mammary cells (MCF10a) were available, we
utilized high quality data from 22 datasets representing
multiple human cell types immuno-precipitated with the
four transcription factors under investigation. FASTQ files
were aligned to a reference human genome (GRCh38)
using the BWA algorithm and peaks were called using
MACS2 to identify transcription factor binding sites. Bed-
tools (v2.25) software was used for intersect analysis with
the putative promoter regions (-3 kb and +1 kb of TSS,
GRCh38 annotation) of the 54 mitotic network genes.
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siRNA transfection and efficiency of knockdown
Small interfering RNAs (siRNAs) targeting mitotic genes
(two siRNAs per gene), transcription factors and AllStars
Negative Control siRNAs were purchased from Qiagen
Inc. The AllStars Negative Control siRNA, which has no
homology to any known mammalian genes, is the most
thoroughly tested and validated negative control siRNA
currently available. Breast cancer cells were seeded at
the desired number in 96-well plates one day prior to
transfection. Cells were transfected with 10 nM siRNAs
using Dharmafect1 transfection regent (Dharmacon) ac-
cording to the manufacturer’s instructions. After trans-
fection with siRNAs for 72 hours, cell viability was
measured using the CellTiter-Glo® assay (Promega). The
RNA level of each gene and the actin control were mea-
sured with QuantiGene® 2.0 Reagent System (Panomics).
The RNA levels relative to actin were compared to
mRNA levels normalized to AllStars Negative control
siRNA.
Results
Defining a mitotic apparatus transcriptional network
We analyzed gene expression profiles for 53 malignant
and non-malignant human breast cancer cell lines [23]
in order to identify the genes involved in mitotic appar-
atus function that had coordinately regulated transcrip-
tional levels (i.e., increased or decreased together
between samples). First, we searched for genes with ex-
pression levels that correlated significantly with the tran-
scriptional levels of the mitotic apparatus genes PLK1,
CENPE, and AURKB across the cell lines. This process
defined a network comprising 272 Affymetrix probes
representing 229 genes (p value of 2.5 × 10−5 based on
1000 permutation tests; Additional file 1: Table S1).
Gene ontology analysis revealed that most of the genes
in this network were involved in mitotic processes
(Additional file 1: Table S2). We then assessed the extent
to which this transcriptional network was coordinately
regulated among samples from two separate primary
breast tumor datasets [24, 31]. Figure 1 shows a mitotic
apparatus network comprising 54 coordinately regulated
transcripts in all three datasets (Additional file 1:
Table S3). This mitotic apparatus network was also
found to be co-regulated in cancers of the lung,
ovary, prostate, brain, blood, and kidney (Additional
file 2: Figure S1A-G), and in immortalized lympho-
blast cell lines (Additional file 2: Figure S1H) and
normal skin samples from crosses between M. spretus
and M. musculus mouse strains [15].
We defined the mitotic network activity index (MNAI)
as the sum of the transcriptional levels of the 54 coordi-
nately regulated mitotic apparatus genes. Additional file 2:
Figure S2 shows that the MNAI was significantly elevated
in tumors relative to normal breast tissues despite
considerable variability in the MNAI across tumors and in
normal tissues. The MNAI was significantly higher in
basal-like cell lines (Fig. 2a) and tumors (Figs. 2b-c)
as compared to luminal subtype cell lines and tumors.
In rank order the MNAI was lowest in normal-like
tumors and luminal-A tumors, with progressively in-
creasing MNAI values for luminal-B tumors, ERBB2-
positive tumors and basal-like breast tumors (82 % of
basal-like tumors exhibited high MNAI). High MNAI
values were similarly enriched (95 % of cases) in integra-
tive cluster 10 (IC10) (Fig. 2c). Figure 3 indicates that pa-
tients with high MNAI values had significantly shorter
disease-free survival (DFS) than patients whose tumors
had low MNAI values in four different breast cancer co-
horts [24, 31–33], whereby patients were stratified by
the upper and lower tertiles of MNAI values. Not
surprisingly, the higher MNAI was significantly asso-
ciated with the higher mitotic accounts defined as the
number of mitotic events in 10 high power fields [34]
(Additional file 2: Figure S3A) and shorter doubling time
in cell lines (Additional file 2: Figure S3B-C). We further
validated the association between MNAI and disease-
specific survival (DSS) in the dataset of 1980 cases from
Curtis et al., which remained significant after adjusting for
standard clinical covariates, including molecular subtype
(Additional file 2: Figure S4).
Genomic mechanisms of mitotic apparatus network
deregulation
The genetically driven mitotic apparatus transcriptional
network identified in mice [15] raised the possibility that
genomic aberrations might contribute to increased mi-
totic activity in human cancer. We explored this possi-
bility by searching for recurrent genome copy number
abnormalities associated with elevated mitotic network
gene expression in two separate breast cancer studies for
which genomic and transcriptional profiles were avail-
able. In particular, we utilized data from a study by Chin
et al., which employed the Affymetrix U133 array to pro-
file gene expression and a bacterial artificial chromo-
some (BAC) array to assay genomic copy number in 101
breast tumors and in a study by Curtis et al., which
employed the Illumina HT12 Bead Array to profile gene
expression and the Affymetrix SNP 6.0 platform to profile
genome copy number in 1980 breast tumors. Strikingly,
both studies showed that regions of amplification at chro-
mosomes 8q24 (120–132 Mbp), 10p15-p12 (0–18 Mbp)
and 12p13 (0–4 Mbp) were associated with increased ex-
pression of multiple genes in the mitotic apparatus net-
work (Fig. 4, Additional file 2: Figure S5, Additional file 3:
Table S5), attesting to the robustness of this signature. In
addition, in the study by Curtis et al. there were strongly
associated amplified regions on 17q24-q25 (55.4–78.5
Mbp). The strength of association between genomic copy
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number and expression in the dataset from Curtis et al. is
shown in Fig. 4a for the FOXM1 and MCM10 genes
(upper panel) and for all 54 mitotic genes in Additional
file 4. The expression of FOXM1 is associated with ampli-
fication of 12p13 where it maps, and with amplification of
the other three regions of the genome. Genomic aberra-
tions significantly associated with the expression levels of
the 54 mitotic apparatus genes are indicated in Fig. 4a. All
but two genes in the mitotic apparatus transcriptional net-
work were associated with the same four regions of gen-
ome amplification in this dataset. The heatmap of copy
number alterations shown in Fig. 4b reveals that the four
regions encoding these genes are co-amplified in tumors
with the highest MNAI. Intriguingly, these regions encode
the transcription factors MYC, ZEB1, SOX9, and FOXM1,
each of which has predicted binding sites in multiple
genes comprising the mitotic apparatus network of 54
genes (Additional file 5: Table S6). Using publicly available
ChIP-sequencing datasets from diverse cell lines (see
“Methods”), we verified that MYC, FOXM1 and ZEB1
bind to all 54 mitotic network genes within the putative
promoter region (−3 kb, +1 kb window around the tran-
scriptional start site) and that ZEB1 binds to the putative
promoters of 45 mitotic network genes.
Therapeutic targeting of high MNAI tumors
We measured quantitative dose responses for 53 breast can-
cer cell lines to inhibitors of PLK1, CENPE and AURKB/C
designated GSK462364 GSK923295 and GSK1070916, re-
spectively (Additional file 6). The concentration required
to inhibit growth by 50 % (GI50) after three days was used
as the quantitative measure of response for each cell line.
Importantly, the ensemble of cell lines mirrored many
transcriptional and genomic features of primary breast
Fig. 1 A conserved mitotic apparatus network in breast cancer cell lines and tumors. Transcripts with expression levels that correlated significantly
with the expression levels of either PLK1, CENPE, or AURKB in 53 breast cancer cell lines (ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) with
accession number E-TABM-157) were identified. A relevance network was constructed based on the correlation between the resultant genes (272 Affy-
metrix probes), with edges drawn between significantly correlated genes (nodes). The mitotic gene network derived in the breast cancer cell lines was
also confirmed in primary breast tumors from dataset 1 (as Chin et al) and dataset 2 (as GSE2034).
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tumors. The GI50 values varied widely among the cell lines
(Additional file 2: Figure S7). Figure 5a shows that, on
average, the GI50 values for GSK1070916, GSK462364,
and GSK923295 were significantly lower in cell lines with
a high MNAI as compared to cells with a low MNAI. This
effect was slightly more pronounced than the difference
between GI50 values for basal and luminal-like tumors
(Fig. 5b).
Interestingly, the responses to the three compounds
were significantly correlated among the cell lines
(Additional file 1: Table S4). This suggests that drugs that
target the mitotic apparatus may be clinically equivalent
as they modulate the same biological function despite the
fact that they inhibit different proteins involved in the
function. As a result, combinations of mitotic apparatus
inhibitors might not have additive or synergistic effects.
We tested this by treating a sensitive (HCC38) and a re-
sistant (MDAMB175) breast cancer cell line with
GSK462364, GSK1070916, and GSK923295 alone and in
pairwise combinations. As shown in Fig. 5c, the combin-
ation of compounds against two different mitotic apparatus
proteins did not increase the response in either cell type.
GSK462364, GSK923295, and GSK1070916 induced cell
apoptosis in sensitive breast cancer cells in a dose-
dependent manner assessed by immunofluorescence
microscopy, but none of the combinations of two com-
pounds significantly increased cell death (Additional file 2:
Figure S8).
In order to identify additional candidate therapeutic
targets within the mitotic apparatus network, siRNAs
were employed to knock down the expression of the 54
genes that comprise the network in MDAMB231 cells.
MBAMD231 was chosen because of its high MNAI.
There was more than 50 % knockdown of mRNA levels
in 40 mitotic network genes (Fig. 6b). Figure 6a shows
that siRNAs targeting 22 genes significantly diminished
growth at 72 hours relative to that for a scrambled
siRNA. The most inhibitory siRNAs targeted PLK1, the
condensin complex component; SMC4, the kinesin family
member; KIF14, the condensin complex regulatory sub-
unit; NCAPD2, the condensing complex subunit 1 com-
ponent; and the ribonucleotide reductase M2 subunit,
Fig. 2 Mitotic network activity is elevated in a subset of breast cancers. Mitotic network activity index (MNAI) defined as the sum of the expression
levels of the 54 mitotic network genes. Heatmaps illustrate mitotic network gene expression in breast cell lines (n = 53) [23] (basal vs. luminal subtype),
p < 0.0001 (a), primary breast tumors from dataset 1 (n = 101) p < 0.001 (b), and primary tumors in the dataset from Curtis dataset. (n = 1980),
p < 0.00001 (c), between basal and luminal tumors (PAM50) and integrated cluster 10 (IC10) vs. other subgroups (ICs) based on analysis of variance.
LumA luminal A, LumB luminal B, Her2 human epidermal growth factor receptor 2, ER estrogen receptor
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RRM2. Protein motif analysis suggests that several of the
22 candidate therapeutic targets defined here are drug-
gable (Additional file 1: Table S3) including the mitotic
checkpoint protein kinase, TTK; the MAPKK-like protein
kinase, PBK [35]; and AURKA, for which a small molecu-
lar inhibitor (MLN8054) [36] is already available and
under evaluation in breast cancer cells.
Discussion
Increased mitotic activity is a hallmark of aggressive can-
cer and is associated with genome instability, increased
proliferative activity, and reduced patient survival in
many types of cancer. In pursuit of mechanisms that in-
crease mitotic activity in breast cancer, we identified a
54-gene mitotic apparatus network that is transcription-
ally upregulated in primary tumors and breast cancer
cell lines with high mitotic activity and/or high prolifera-
tive capacity. In parallel, we defined a mitotic network
activity index (MNAI) as a quantitative measure of the
transcriptional activity of the entire 54-gene network
and showed that high MNAI is enriched amongst basal-
like or IC10 tumors. We further showed that elevated
MNAI is significantly associated with poor prognosis in-
dependent of standard clinical covariates.
Our data suggest that high MNAI and the elevated ex-
pression of the mitotic network genes can be explained,
in part, by co-amplification of regions of chromosomes
8q24, 10p15-p12, 12p13, and 17q24-q25, which encode
the transcription factors MYC, ZEB1, FOXM1, and
SOX9, respectively. Indeed, each of the 54 genes in the
mitotic apparatus network have predicted binding sites
for one or more of these transcription factors and we
verified the majority of binding sites for MYC, FOXM1,
ZEB1, and SOX9 using publicly available ChIP-seq
datasets. A genomic mechanism of mitotic apparatus
network activation in cancer is consistent with the ob-
servation that the transcriptional activity of the mitotic
network appears to be under genetic control in normal
tissues both in the mouse [15] and human lymphocytes.
These amplified transcription factors are known to play
important roles in normal tissue development and/or
stem cell biology. In particular, MYC has been impli-
cated in reprogramming somatic cells to become pluri-
potent stem cells [37]. ZEB1 has been associated with
the epithelial-to-mesenchymal transition and cell migra-
tion [38]. SOX9 has been implicated in neural crest tis-
sue development, the maintenance of multipotency, and
Notch-mediated cell fate determination [39, 40]. FOXM1
is a transcription factor implicated in mitosis, a compo-
nent of the 54-gene mitotic network, and a known tran-
scriptional target of estrogen receptor alpha, with an
important role in breast cancer endocrine biology [41].
These diverse functions may explain why tumors with
high genome amplification-associated MNAI also have
a b
c d
Fig. 3 Association between mitotic network activity and survival time. Kaplan-Meier curves are shown for tumors with the highest one third of
mitotic network activity index (MNAI) values and the lowest one third of MNAI values. Higher mitotic network activity was significantly associated
with reduced survival time in four independent breast cancer studies based on the log-rank test. a Dataset 1, p < 0.05. b Dataset 2, p < 0.0005. c Dataset
3, p < 0.0001. d Dataset 4, p < 0.0001
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increased invasive potential and take on features associ-
ated with stem cells. Several cell proliferation signatures
have been previously reported and shown to be associ-
ated with poor prognosis in subsets of breast cancer pa-
tients [42, 43], and not surprisingly these gene sets
overlap with the MNAI. For example, many of the genes
in the 54-gene mitotic apparatus network are included
in the CIN25 gene signature reported to be associated
with genome instability and reduced survival in multiple
tumor types [4]. The association with genomic instability
may stem from the deregulation of multiple mitotic
apparatus genes via co-amplification of key transcription
factors that influence genome instability both directly by
interfering with DNA repair and the mechanical aspects
of chromosome segregation and indirectly by deregulat-
ing checkpoint genes that normally function to inhibit
cell cycle progression in cells with mechanical or gen-
omic aberrations. Gene ontology analysis of the 54-gene
mitotic apparatus signature indicates that CCNB1,
CENPE, DLGAP5, HJURP, KIF2C, NCAPD2, NCAPG,
NCAPH, NDC80, PTTG1, and SMC4 are involved in
mechanical aspects of chromosome segregation, whereas
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alterations for loci significantly associated with the expression of mitotic network genes. Amplified regions on chromosome 8q24 (120–132 Mb),
10p15-p12 (0–17.8 Mb), 12p13 (0–4 Mb), and 17q24-q25 (55.4–78.5 Mb) are indicated, where samples have been ordered by their mitotic network
activity index. c These loci include the transcription factors MYC, ZEB1, FOXM1 and SOX9, each of which has predicted binding sites in multiple mitotic
network genes, where edges connecting transcription factors to mitotic network genes based on binding site predictions are indicated in red and sites
verified by ChIP-seq are shown in blue. MNAI mitotic network activity index
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CHEK1, EXO1, PTTG1, RFC3, and TYMS are involved
in DNA repair, and finally, BUB1, BUB1B, CCNA2,
CCNB1, CENPE, CHEK1, GSTE1, PLK1, and TTK are
cell cycle checkpoint genes.
Genome amplification-driven activation of the mitotic
apparatus network raises the possibility that cancers with
this mechanism of activation have become “addicted” to
the activation and thus, will be more sensitive to agents
that target the activated network proteins than tumors
with lower activity. Consistent with this, we have
shown that the small molecule inhibitors GSK462364,
GSK923295, and GSK1070916 that target the network
proteins PLK1, CENPE, and AURKB/C, respectively,
inhibit the growth of breast cancer cell lines with high
MNAI at lower concentrations than cell lines with low
MNAI. These results also are supported by the report that
treatment with the aurora kinase inhibitor, VX-680, select-
ively kills cells that over express MYC [44]. siRNA knock-
down experiments show that inhibition of most genes in
the mitotic apparatus network significantly represses
growth, and implicate AURKA, TTK, MELK, and PBK as
additional druggable proteins in the network. Based on
our previous data (AACR 2008, Abstract# 2397) and
others reported, these inhibitors not only induced the ac-
cumulation of cells with 4N and ≥4N DNA content, sug-
gesting that DNA replication could occur in the absence
of cytokinesis, indicative of a cell-cycle block in either G2
phase or mitosis, but also induced apoptosis in human
cancer cell lines. Although GSK1070916 has potent activ-
ity against proliferating cells, a dramatic shift in potency is
observed in primary, non-dividing tumors [45]. These ob-
servations indicate that mitotic apparatus inhibitors might
be best targeted to aggressive cancers with high MNAI
and/or co-amplification of MYC, ZEB1, FOXM1, and
SOX9, thereby lowering the dose required for effective
treatment and correspondingly lowering overall toxicity.
Our studies of pairwise combinations of GSK462364,
GSK923295, and GSK1070916 show that toxicity does not
appear to be additive. Thus, combinations of compounds
targeting multiple mitotic apparatus proteins might be de-
ployed either together or sequentially to counter thera-
peutic resistance. This approach might lead to more
durable treatment of the most aggressive forms of breast
cancer.
Conclusions
We presented evidence in this paper that high mitotic
activity in a subset of breast cancers is caused, in part,
by co-amplification of four regions of the genome that
encode transcription factors that regulate a mitotic ap-
paratus network playing important roles in cell cycle
traverse, DNA repair and chromosome segregation. We
a b c
Fig. 5 Dose response in breast cancer subtypes. Responses to GSK462364, GSK923295, and GSK1070916 were assayed for compounds individually
or in combination in cell lines representing different breast cancer subtypes. a Responses in cell lines with a high mitotic network activity index
(MNAI) and a low MNAI, and b responses in basal and luminal breast cancer cell lines were assessed using the two-tailed Mann-Whitney U test.
c Responses to GSK462364, GSK923295 and GSK1070916 administered individually or in pairwise combination in breast cancer cell lines with high
(HCC38) or low (MDAMB175) MNAI
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defined a molecular signature that can be measured to
identify tumors with high mitotic network activity and
we showed that these tumors are likely to be preferen-
tially sensitive to mitotic apparatus protein inhibitors,
and combining mitotic apparatus protein inhibitors will
reduce development of therapeutic resistance to these
inhibitors.
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normalizing to mRNA levels after treatment with a control siRNA
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